Cargando…

Budesonide/Formoterol Enhances the Expression of Pro Surfactant Protein-B in Lungs of COPD Patients

RATIONALE & AIM: Pulmonary surfactants are essential components of lung homeostasis. In chronic obstructive pulmonary disease (COPD), surfactant expression decreases in lungs whereas, there is a paradoxical increase in protein expression in plasma. The latter has been associated with poor health...

Descripción completa

Detalles Bibliográficos
Autores principales: Um, Soo Jung, Lam, Stephen, Coxson, Harvey, Man, Shu Fan Paul, Sin, Don D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873417/
https://www.ncbi.nlm.nih.gov/pubmed/24386300
http://dx.doi.org/10.1371/journal.pone.0083881
_version_ 1782297110062825472
author Um, Soo Jung
Lam, Stephen
Coxson, Harvey
Man, Shu Fan Paul
Sin, Don D.
author_facet Um, Soo Jung
Lam, Stephen
Coxson, Harvey
Man, Shu Fan Paul
Sin, Don D.
author_sort Um, Soo Jung
collection PubMed
description RATIONALE & AIM: Pulmonary surfactants are essential components of lung homeostasis. In chronic obstructive pulmonary disease (COPD), surfactant expression decreases in lungs whereas, there is a paradoxical increase in protein expression in plasma. The latter has been associated with poor health outcomes in COPD. The purpose of this study was to determine the relationship of surfactants and other pneumoproteins in bronchoalveolar lavage (BAL) fluid and plasma to airflow limitation and the effects of budesonide/formoterol on this relationship. METHODS: We recruited (clinical trials.gov identifier: NCT00569712) 7 smokers without COPD and 30 ex and current smokers with COPD who were free of exacerbations for at least 4 weeks. All subjects were treated with budesonide/formoterol 400/12 µg twice a day for 4 weeks. BAL fluid and plasma samples were obtained at baseline and the end of the 4 weeks. We measured lung-predominant pneumoproteins: pro-Surfactant Protein-B (pro-SFTPB), Surfactant Protein-D (SP-D), Club Cell Secretory Protein-16 (CCSP-16) and Pulmonary and Activation-Regulated Chemokine (PARC/CCL-18) in BAL fluid and plasma. RESULTS: BAL Pro-SFTPB concentrations had the strongest relationship with airflow limitation as measured by FEV(1)/FVC (Spearman rho = 0.509; p = 0.001) and FEV(1)% of predicted (Spearman rho =  0.362; p = 0.028). Plasma CCSP-16 concentrations were also significantly related to airflow limitation (Spearman rho = 0.362; p = 0.028 for FEV(1)% of predicted). The other biomarkers in BAL fluid or plasma were not significantly associated with airflow limitation. In COPD subjects, budesonide/formoterol significantly increased the BAL concentrations of pro-SFTPB by a median of 62.46 ng/ml (p = 0.022) or 48.7% from baseline median value. CONCLUSION: Increased severity of COPD is associated with reduced Pro-SFTPB levels in BAL fluid. Short-term treatment with budesonide/formoterol increases these levels in BAL fluid. Long term studies will be needed to determine the clinical relevance of this observation.
format Online
Article
Text
id pubmed-3873417
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-38734172014-01-02 Budesonide/Formoterol Enhances the Expression of Pro Surfactant Protein-B in Lungs of COPD Patients Um, Soo Jung Lam, Stephen Coxson, Harvey Man, Shu Fan Paul Sin, Don D. PLoS One Research Article RATIONALE & AIM: Pulmonary surfactants are essential components of lung homeostasis. In chronic obstructive pulmonary disease (COPD), surfactant expression decreases in lungs whereas, there is a paradoxical increase in protein expression in plasma. The latter has been associated with poor health outcomes in COPD. The purpose of this study was to determine the relationship of surfactants and other pneumoproteins in bronchoalveolar lavage (BAL) fluid and plasma to airflow limitation and the effects of budesonide/formoterol on this relationship. METHODS: We recruited (clinical trials.gov identifier: NCT00569712) 7 smokers without COPD and 30 ex and current smokers with COPD who were free of exacerbations for at least 4 weeks. All subjects were treated with budesonide/formoterol 400/12 µg twice a day for 4 weeks. BAL fluid and plasma samples were obtained at baseline and the end of the 4 weeks. We measured lung-predominant pneumoproteins: pro-Surfactant Protein-B (pro-SFTPB), Surfactant Protein-D (SP-D), Club Cell Secretory Protein-16 (CCSP-16) and Pulmonary and Activation-Regulated Chemokine (PARC/CCL-18) in BAL fluid and plasma. RESULTS: BAL Pro-SFTPB concentrations had the strongest relationship with airflow limitation as measured by FEV(1)/FVC (Spearman rho = 0.509; p = 0.001) and FEV(1)% of predicted (Spearman rho =  0.362; p = 0.028). Plasma CCSP-16 concentrations were also significantly related to airflow limitation (Spearman rho = 0.362; p = 0.028 for FEV(1)% of predicted). The other biomarkers in BAL fluid or plasma were not significantly associated with airflow limitation. In COPD subjects, budesonide/formoterol significantly increased the BAL concentrations of pro-SFTPB by a median of 62.46 ng/ml (p = 0.022) or 48.7% from baseline median value. CONCLUSION: Increased severity of COPD is associated with reduced Pro-SFTPB levels in BAL fluid. Short-term treatment with budesonide/formoterol increases these levels in BAL fluid. Long term studies will be needed to determine the clinical relevance of this observation. Public Library of Science 2013-12-26 /pmc/articles/PMC3873417/ /pubmed/24386300 http://dx.doi.org/10.1371/journal.pone.0083881 Text en © 2013 Um et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Um, Soo Jung
Lam, Stephen
Coxson, Harvey
Man, Shu Fan Paul
Sin, Don D.
Budesonide/Formoterol Enhances the Expression of Pro Surfactant Protein-B in Lungs of COPD Patients
title Budesonide/Formoterol Enhances the Expression of Pro Surfactant Protein-B in Lungs of COPD Patients
title_full Budesonide/Formoterol Enhances the Expression of Pro Surfactant Protein-B in Lungs of COPD Patients
title_fullStr Budesonide/Formoterol Enhances the Expression of Pro Surfactant Protein-B in Lungs of COPD Patients
title_full_unstemmed Budesonide/Formoterol Enhances the Expression of Pro Surfactant Protein-B in Lungs of COPD Patients
title_short Budesonide/Formoterol Enhances the Expression of Pro Surfactant Protein-B in Lungs of COPD Patients
title_sort budesonide/formoterol enhances the expression of pro surfactant protein-b in lungs of copd patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873417/
https://www.ncbi.nlm.nih.gov/pubmed/24386300
http://dx.doi.org/10.1371/journal.pone.0083881
work_keys_str_mv AT umsoojung budesonideformoterolenhancestheexpressionofprosurfactantproteinbinlungsofcopdpatients
AT lamstephen budesonideformoterolenhancestheexpressionofprosurfactantproteinbinlungsofcopdpatients
AT coxsonharvey budesonideformoterolenhancestheexpressionofprosurfactantproteinbinlungsofcopdpatients
AT manshufanpaul budesonideformoterolenhancestheexpressionofprosurfactantproteinbinlungsofcopdpatients
AT sindond budesonideformoterolenhancestheexpressionofprosurfactantproteinbinlungsofcopdpatients